Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Revisions to selling prices and other terms, product development and renewals, home-placement sales, expansion of store private-label products, cross-selling, sales of summer and heatstroke-prevention products, and firm demand for the core 12-liter bottles
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥1,813 million (YoY +5.3%) |
| Operating profit | ¥103 million (YoY +11.5%) |
| Ordinary income | ¥107 million (YoY +11.5%) |
| Profit attributable to owners of the parent | ¥73 million (YoY +9.2%) |
| Net income per share | ¥6.87 |
| Equity ratio | End of the current fiscal period 46.5% / End of previous period 48.8% |
| Total assets | ¥5,670 million |
| Net assets | ¥2,636 million |
| Full-year earnings forecast | Net Sales ¥6,150 million (YoY -6.4%) / Operating profit ¥133 million (YoY +4.4%) / Ordinary income ¥145 million (YoY +3.8%) / Net income ¥85 million (YoY +2.3%) |
| Annual Dividend Forecast | ¥5 → ¥5（0.0%） |
| Segment revenue | Household pharmaceuticals and other products sales business (retail and wholesale divisions) ¥1,630 million (YoY +6.6%), Water Sales Division ¥183 million (YoY -4.8%) |
| Segment profit | Household pharmaceuticals and other products sales business (retail and wholesale divisions) ¥83 million (YoY +23.7%), Water Sales Division ¥19 million (YoY -21.3%) |
| Depreciation and amortization | ¥11,391 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on redemption of investment securities ¥38 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 11,660,734 Shares |
| Treasury Shares at Period-End | 983,986 Shares |
| Factors Behind Changes in Business Performance | Revisions to selling prices and other terms, product development and renewals, home-placement sales, expansion of store private-label products, cross-selling, sales of summer and heatstroke-prevention products, and firm demand for the core 12-liter bottles |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the household pharmaceuticals and other products sales business, the company worked on revising selling prices and other terms, developing and renewing products, consignment sales including home-placement sales, expanding store private-label products and cross-selling, and selling summer and heatstroke-prevention products. In the water sales business, demand for the core 12-liter bottles remained firm, supported by disaster-preparedness stockpiling and heatstroke-prevention needs, while sales of water-related products fell below the year-earlier period.